InspireMD cuts warrant exercise price to USD 0.77, extends expiry to May 2028 or post-FDA approval window

• InspireMD amended portions of its Series J and Series K warrants to align exercisability with expected FDA approval of CGuard Prime 80 cm.
• Changes cover about 4,800,000 Series J underlying shares and 9,500,000 Series K underlying shares held by participating holders.
• Amended warrants reset the exercise price to $0.77 per share, tied to the Sept. 18 close.
• Termination revised to the earlier of May 15, 2028 or 20 trading days after an FDA-approval announcement for CGuard Prime 80 cm.
• Full exercise could deliver up to $11 million in gross proceeds; no additional warrants were issued under the amendments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609210900PRIMZONEFULLFEED1001273807) on September 21, 2026, and is solely responsible for the information contained therein.